Wells Fargo on Soleno Therapeutics Inc. (SLNO): 'We Think Shares Should Trade Up at Least +20% on ACAD Failure'

Wells Fargo analyst Derek Archila reiterated an Overweight rating and $123.00 price target on Soleno Therapeutics Inc. (NASDAQ: SLNO).

The analyst comments "What happened? ACAD's Ph3 PWS trial of intranasal carbetocin (ACP-101) failed to meet the primary endpoint, change from baseline to week 12 on HQ-CT. In addition, there was no separation from placebo on any secondary endpoints according to the PR. The safety and tolerability profile was consistent with prior data. Looking ahead, ACAD has decided to discontinue the development of ACP-101 in PWS. What does this mean for SLNO? We had estimated ACP-101's failure could offer +20% upside for SLNO shares. The next competitor Ph3 dataset will be from ARD-101 in 3Q26, but we will see some Ph2 data from RYTM's IMCIVREE by YE25. For now, SLNO remains the SOC in PWS, and the only drug approved."

For an analyst ratings summary and ratings history on Soleno Therapeutics Inc. click here. For more ratings news on Soleno Therapeutics Inc. click here.

Shares of Soleno Therapeutics Inc. closed at $56.85 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery